Shared Decision-Making Tool Helps Pregnant Women With Opioid Use Disorder
Investigators aimed to determine the number of women who came to a treatment decision using the shared decision-making tool.
Opioid-Use Disorder
Direct-to-Doctor Payments May Increase Opioid Prescribing
Physicians who receive direct pharmaceutical payments for opioid prescribing prescribe more opioids, especially hydrocodone and oxycodone.
Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
The use of benzodiazepine, only if prescribed, may not affect retention of methadone medication-assisted treatment.
Extended-Release Naltrexone Improves Psychiatric Disorders During Addiction Therapy
Changes in anxiety, depression, or insomnia symptoms were examined in patients with opioid use disorder taking extended-release naltrexone or buprenorphine-naloxone.
Discharge One Hour After Naloxone for OD May Be Option
A new rule can determine whether patients can be safely discharged from the ER after a one-hour observation period following prehospital naloxone administration.
Dental Procedure-Related Opioid Exposure and Later Risk for Opioid Abuse
A substantial proportion of adolescent and young adults receiving opioids for dental procedures may be at higher risk for later opioid use and abuse.
CBT Program Effective for Chronic Pain and Opioid Use Disorder
Cognitive behavioral therapy was found to be more effective in reducing the use of nonmedical opioids compared with standard methadone drug counseling in patients with chronic pain and opioid use disorder enrolled in methadone maintenance treatment programs.
reSET-O Digital Therapeutic for Opioid Use Disorder Now Available
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
FDA Advisory Panels: Prescribe Naloxone With Opioid Painkillers
The labels of prescription opioid painkillers should advise doctors to consider simultaneously prescribing the opioid overdose antidote naloxone, 2 US FDA advisory panels recommend.
Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder
Buprenorphine-naloxone is cost-effective compared with extended-release naltrexone for treating opioid use disorder.
Next post in Addiction
